SecProbe.io

April 7, 2014

Via E -mail
Nevan Elam
Chief Executive Officer
AntriaBio, Inc.
890 Santa Cruz Avenue
Menlo Park , CA 94025

Re: AntriaBio, Inc.
 Preliminary  Proxy Statement on Schedule 14C
March 31, 2014
File No. 00 0-54495

Dear Mr. Elam :

We have limited our rev iew of your filing to the issue  addressed in the following
comment .

Please respond to this letter by amending your filing and providing the requested
information .  If you do not believe our comment  applies to your facts and circumstances or do
not believe an amendment is appropriate, please tell us why in your response.

After reviewing any amendment to your filing and the information you provide in
response to our c omment , we may have  additional comments.

Proposal 1
Amendment to the Certificate of Incorporation to Effect a 1 for 6 Reverse Split of the
Company’s Issued and Outstanding Common Stock, page 4

1. We note your disclosure that, in connection w ith the Reverse S plit, you do not intend to
change the number of shares of common stock authorized , resulting in additional
authorized but unissued shares th at may be issued by your Board of Directors in its
discretion .  Please disclose whether you currently have, or do not have, any plans with
respect to the se additional authorized but unissued shares.  If such plans exist, please
disclose all material information.

We urge all persons who are responsible for the accuracy and adequacy of the disclosure
in the  filing to be certain that the filing includes the information the Securities Exchange Act of
1934 and all applicable Exchange Act rules require.   Since the company and its management are
in possession of all facts relating to a company’s disclosure, they are responsible for the accuracy
and adequacy of the disclosures they have made.

Nevan Elam
AntriaBio , Inc.
April 7, 2014
Page 2

  In responding to our comments, please provide  a written statement from the company
acknowledging that:

 the company is responsible for the adequacy and accuracy of the dis closure in the filing;

 staff comments or changes to disclosure in response to staff comments do not foreclose
the Commission from taking any action with respect to the filing; and

 the company may not assert staff comments as a defense in any proceeding initiated by
the Commission or any person under the federal securities laws of the United States.

Please contact  Christina De Rosa at (202) 551 -3577 , Dan Greenspan at (202) 551 -3623  or
me at (202) 551 -3715  with any questions.

Sincerely,

 /s/ Daniel  Greenspan for

Jeffrey P. Riedler
Assistant Director